🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesMetabolic syndrome reversal — my 5 criteria all normalized Page 2

Metabolic syndrome reversal — my 5 criteria all normalized

steve_okc Wed, May 27, 2026 at 3:47 AM 20 replies 513 viewsPage 2 of 4
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
May 27, 2026 at 5:29 AM#6
DataDave said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

Last edited: May 27, 2026 at 6:29 AM
31 1mona_PHX, andrew_nyc, Dr.EndoEP and 28 others
Reply Quote Save Share Report
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
May 27, 2026 at 6:08 AM#7
steve_okc said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 27 → 13 → 5 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

30 0Dr.ObesityLA, NurseKim_ATL, paul_denver and 27 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
May 27, 2026 at 6:47 AM#8
Dr.ReproEndo said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 20%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

Last edited: May 27, 2026 at 12:47 PM
29 24tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 26 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
AttorneyGrant
Member
567
2,890
Apr 2024
Washington, DC
May 27, 2026 at 7:26 AM#9

Following on from TrialTracker_MD — and this may be the naive question:

Was that from a primary source or from a summary of one?

28 23pat_auckland, Dr.GastroMayo, JakeBK_lifts and 25 others
Reply Quote Save Share Report
steve_okc
Member
489
2,123
Jul 2024
Oklahoma City, OK
May 27, 2026 at 10:34 AM#10
roxy_nash said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 20%.

My labs after 12 months on glycaemic control: A1C 6.4%, fasting glucose 94 mg/dL, fasting insulin 9 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 8.3% and fasting glucose was 139 mg/dL. The improvement has been dramatic and consistent.

16 16KetoKyle, CanadaChris, ZaraB_AL and 13 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register